March 29, 2022
MGI is pleased that the Court in the Northern District of California denied Illumina's request to overturn the jury's decision invalidating the '444 patent. The 444 patent was not set to expire until June 2023. Because the other patents Illumina asserted against MGI's CoolMPSTM technology expire in August 2022, MGI now has the ability to commercialize [...]
March 29, 2022
SEATTLE -- Curi Bio, a leading developer of human stem cell-based platforms and technologies for drug discovery, today announced the exclusive commercial acquisition from StemBioSys of the CarTox™ technology platform for calcium and voltage optical mapping. In parallel, Curi Bio announced it will commercialize the technology through its newly announced product: the Nautilus™ optical mapping system. By [...]
Fortis Life Sciences Partners with AccuGenomics to Expand Genomics Portfolio
March 29, 2022
WALTHAM, MA - Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced it is the exclusive channel partner for AccuGenomics in the United States, with co-exclusive rights in Europe. Under the agreement, Fortis will help expand customer access to AccuGenomics’ patented SNAQ™-SEQ Internal [...]
M2GEN Appoints Eric Anderson as Chief Financial Officer
March 29, 2022
Anderson brings over 25 years of operational and financial leadership experience across the life sciences, technology, and retail industries Joseph R. Smith, CPA, CGMA, to retire in April 2022 TAMPA, FL -- M2GEN, a bioinformatics company accelerating discoveries in oncology research through industry leading data and analytics, today announced that Eric Anderson will join the company as new [...]
Vector Laboratories Adds Kum Ming Woo to Executive Team as Vice President, Operations
March 29, 2022
Woo bringing key manufacturing experience and turnaround time reductions to proteomic and glycomic-focused company Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced that Kum Ming Woo has joined its executive team as Vice President, Operations. In this new role, he will oversee Vector Laboratories’ work in further innovating its manufacturing processes [...]
Mission Bio Launches First-in-Class Single-Cell Genomics Solid Tumor Solution on Tapestri Platform
March 29, 2022
Tapestri Solution for Solid Tumor Research offers improved CNV analysis capability, in addition to breast cancer and glioblastoma research panels SOUTH SAN FRANCISCO, Calif. – Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today launched the Tapestri Solution for Solid Tumor Research. This new end-to-end single-cell DNA sequencing workflow on the Tapestri Platform [...]
March 29, 2022
Ion Torrent Genexus Dx Integrated Sequencer enables rapid NGS for diagnostic applications and clinical research CARLSBAD, Calif. -- Thermo Fisher Scientific today launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in as little as a single day. Designed for use in clinical laboratories, the fully [...]
March 29, 2022
Ampersand investment opportunity Syft is pleased to announce that it has reached an agreement with Ampersand Capital Partners (Ampersand) to invest $22.8m in Syft, subject to shareholder approval. Ampersand will subscribe to 17,545,000 convertible preference shares, equivalent to 19.6% of the total shares post-investment, at a price of $1.30 per share. Ampersand is a Boston, [...]
March 29, 2022
Cambridge, UK – Cresset Discovery, provider of CADD expertise for drug discovery, is collaborating with the Translation team at The Francis Crick Institute as expert computational chemist in residence. Computational chemistry is a powerful method in tool development and drug discovery. It enables chemists to predict the physical properties and biological activity of compounds prior to synthesis [...]
Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve
March 29, 2022
Fully silent Fc-engineered antibodies accessible for therapeutic antibody development REDCAR and OXFORD, United Kingdom -- Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve's Fc silencing technology. The agreement provides Absolute Antibody clients with easy license-free access to the new STR [...]

